[Use of phospholipids (Fibraccel) for hemostasis in thrombocytopenic-thrombocytopathic patients].
Eight thrombocytopenic/pathic patients received an intravenous infusion of phospholipids. In-vitro-bleeding test, thrombelastography and resonance thrombography were performed in order to show the hemostatic effect. There was no case in which phospholipids had an efficacy comparable to the transfusion of platelets. Two patients suffered from a severe anaphylactoid reaction after the administration of phospholipids.
Dietrich
G
G
Abteilung für Transfusionsmedizin und Gerinnungsphysiologie, Philipps-Universität Marburg.
Söhngen
D
D
Kretschmer
V
V
D000293:Adolescent; D001760:Bleeding Time; D001780:Blood Coagulation Tests; D001791:Blood Platelet Disorders / Q000097:blood / Q000628:therapy*; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals; D013921:Thrombocytopenia / Q000097:blood / Q000628:therapy*
D006490:Hemostatics; D009930:Organic Chemicals; C049026:fibraccel
Einsatz von Phospholipiden (Fibraccel) zur Blutstillung bei thrombozytopenisch-thrombozytopathischen Patienten.